Debevoise & Plimpton LLP is advising Guggenheim Securities as financial advisor to atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company, in its strategic merger with Beckley Psytech, a private clinical-stage biopharmaceutical company. As a part of the transaction, the strategic merger will create a mental health company named atai Beckley, focusing on rapid-acting psychedelic treatments. For more information, please see the company’s press release.

The Debevoise team is led by M&A partners Andrew Bab and Gordon Moodie and counsel Sarah Jacobson.